



Professor Sir Peter Horby, Professor Sir Martin Landray  
RECOVERY trial Co-chairs  
Nuffield Department of Population Health  
Oxford

6<sup>th</sup> November 2025

Dear Peter and Martin

**RECOVERY trial DMC report**

I reviewed the RECOVERY trial safety and efficacy data that were available for patients randomised by 13<sup>th</sup> October 2025.

For the interventions for influenza, the number of individuals included in the comparison of each agent with its control was respectively: Baloxavir marboxil (768), Oseltamavir (232) and Dexamethasone (312).

The comparison of dexamethasone with its control in community acquired pneumonia included 1176 patients.

The dataset included 1 woman who was pregnant at entry and 10 children.

In the light of the available trial data and all relevant external information, I saw no cogent reason to modify the protocol or intake to the study.

The DMC will next review the data for all treatments in about 6 months time (or sooner if there is a marked increase in recruitment).

Yours sincerely

Professor Peter Sandercock, MA, DM, FRCPE  
Chairman RECOVERY trial DMC  
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

CENTRE DIRECTOR Professor S Chandran  
Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie  
Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock  
Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK  
t: +44 (0)131 465 9602 / w: [www.ccbs.ed.ac.uk](http://www.ccbs.ed.ac.uk) / e: [Peter.sandercock@ed.ac.uk](mailto:Peter.sandercock@ed.ac.uk)